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aims: To evaluate the role of human leukocyte antigen (HLA) class II DQB1*0201 and 
DQA1*0102 in the risk of antituberculosis drug (ATD)-induced hepatotoxicity (ATDH) in a 
cohort of tuberculosis patients of Caucasian origin from Spain.
Methods: Matched case-control study including active tuberculosis (TB) patients from 
Spain (Caucasian) treated with first-line ATD (Isoniazid, Rifampin, and Pyrazinamide). 
Presence or absence of HLA class II DQB1*0201 and DQA1*0102 alleles were com-
pared between cases and controls.
results: We included 110 TB patients, 55 ATDH cases, and 55 sex-matched controls. 
The analysis of the presence of HLA-DQB1*0201 and HLA-DQA*0102 did not show 
significative differences between both groups [presence of HLA-DQB1*0201 53.6% of 
the cases vs. 45.4% of the controls, OR: 1.63 95% CI (0.62–4.52) p = 0.38; presence 
of HLA-DQA*0102 7.5% of cases vs. 20% of controls, OR: 0.36 95% CI (0.08–1.23) 
p =  0.12]. After multivariate logistic regression analysis including in the model, other 
potential risk factors of hepatotoxicity HLA class II DQB1*0201 and DQA1*0102 alleles 
were not found significantly associated with the risk of development ATDH. We could not 
demonstrate an association between HLA-DQA1*0102 and HLA-DQB1*0201 with the 
risk of ATDH in this Caucasian population of Spanish origin.
Keywords: DQB1*0201, DQa1*0102, hepatitis, pharmacogenetics susceptibility, first-line antituberculosis drugs
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; ATD, antituberculosis drugs; ATDH antitubercu-
losis drugs-induced hepatotoxixty; BIL, bilirubin; BMI, body mass index; CEIC, Ethical Committee of Galicia; GGT, gamma 
glutamyl transpeptidase; HLA, human leukocyte antigen; INH, isoniazid; IQR, interquartile range; PCR, polymerase chain 
reaction; PZA, pyrazinamide; RIF, rifampicin; SBT, sequence based typing; SD; TB, tuberculosis; IU, international units; ULN, 
upper limit of normal.
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inTrODUcTiOn
Tuberculosis (TB) continues to be a global health problem 
despite the availability of effective therapies. Hepatotoxicity is 
one of the most important side effects of first-line antituber-
culosis drugs (ATD) that could lead to increase in morbidity 
disease because of treatment interruptions and negative impact 
in treatment compliance including increasing costs (1, 2). The 
first-line ATD-induced hepatotoxicity (ATDH) is isoniazid 
(INH), rifampicin (RIF), and pyrazinamide (PZA). Many risk 
factors for ATDH have been reported, and its incidence depends 
on the number of risk factors, varying from 5.8 to 24.2% 
(1–5). Genetic susceptibility to ATDH has been the subject 
of study during last years focusing in genes encoding phase I 
and II metabolic enzymes, and the risk has been significantly 
associated with certain genetic polymorphisms (3, 6–11). 
Human leukocyte antigen (HLA) class I and II drug-induced 
hepatotoxicity associations have been identified with other 
drugs and also in healthy individuals with alanine transami-
nase (ALT) elevations (7). Each HLA associations points to 
a role for an immune mechanism. Even that the majority of 
recently published studies on ATDH have been concerned with 
polymorphisms affecting drug-metabolizing enzymes, there are 
evidence that some HLA class II alleles are related to the risk 
of ATDH in the Indian and Chinese population (12, 13). The 
purpose of this study is to evaluate the risk of ATDH related 
to HLA class II DQB1*0201 and DQA1*0102 in a cohort of 
TB patients of Caucasian origin from Spain.
MaTerials anD MeThODs
study Design
This individually matched case-control study was nested in a 
cohort of 1,200 patients from Caucasian origin with active TB 
that had been treated between January 1998 and December 
2008 at the TB Units in Complexo Hospitalario Universitario 
de Vigo, Pontevedra, and A Coruña (Galicia, Spain). Some 
characteristics of this cohort were reported in previous 
publications (5, 8, 9). We included all cases of ATDH that 
fulfilled the inclusion criteria. The control group consisted of 
sex- and drug-matched patients that showed no evidence of 
ATDH, selected consecutively from the same cohort. The study 
participants should follow the inclusion criteria: (a) age between 
15 and 75 years old, (b) microbiological demonstration of active 
TB, (c) treatment with regimens that included INH, RIF, and 
PZA at the usual drug dosages (INH 5 mg/kg/day – maximum 
300  mg/day, RIF 10  mg/kg/day – maximum 600  mg/day, and 
PZA 25–30  mg/kg/day – maximum 2,500  mg/day), and (d) 
adequate compliance. Exclusion criteria were: (a)  increased 
baseline serum transaminases [aspartate aminotransferase 
(AST) and/or alanine aminotransferase (ALT)], normal values 
≤40 IU/L, (b) positive serological testing for the human immu-
nodeficiency virus, hepatitis B virus, or hepatitis C virus, (c) 
regular alcohol intake or concomitant use of hepatotoxic drugs, 
(d) history of chronic liver disease, (e) pregnancy, or (f) no or 
poor adherence to treatment.
Diagnosis of antituberculosis  
Drug-induced hepatotoxicity
Antituberculosis drug-induced hepatotoxicity was defined as an 
increase in serum transaminase (either aspartate aminotransferase 
or alanine aminotransferase) to values higher than three times the 
upper limit of normal (ULN) (i.e., >120 IU/L) at any time during 
the treatment period (1). The degree of severity of hepatotoxicity 
was gaged by the peak level of serum transaminases, and classified 
according to the Toxicity Classification Standards (10).
standard Follow-up of Patients on 
antituberculosis Drug Therapy
In this cohort, patients on antituberculosis drug therapy received a 
routine follow-up of clinical assessments every 2 weeks during the 
first month, and thereafter, monthly until completion of therapy. 
Routine liver function tests [blood cell counts and biochemical 
assays for serum AST, ALT, gamma glutamyl transpeptidase 
(GGT), and bilirubin (BIL)] were performed 15–30  days after 
the beginning of treatment, at the end of 2 and 4  months, and 
at 2-month intervals thereafter, when treatments lasted for more 
than 6 months. Clinical and laboratory check-ups were performed 
more frequently when hepatitis symptoms or abnormal serum 
transaminase levels were observed. All patients were warned 
verbally and in writing of possible hepatotoxicity symptoms and 
were provided with an emergency contact telephone number. 
Adherence to treatment was verified by detection of INH metabo-
lites in urine specimens and by tablet counts at every visit.
genotyping Protocol
Blood was collected by venipuncture, and genomic DNA was iso-
lated with Flexi Gene DNA Kit (QIAGEN) following the instruc-
tions of manufacturer (Supplementary Material). The HLA class II 
region (second exon) was amplified by polymerase chain reaction 
(PCR). Specifically DQB1*0201 exon 2 genotype was detected by 
PCR as previously described with minor modifications (14, 15).
statistical analyses
Qualitative variables were expressed as percentages and absolute 
frequencies, and quantitative variables as the median and inter-
quartile range (IQR) or median and SD. Qualitative variables were 
compared using the McNemar test. Quantitative variables were 
analyzed using the Wilcoxon test. A logistic regression model was 
developed in order to evaluate the risk of ATD-induced hepatitis 
in the presence or absence of HLA DQB1*0201 and DQA1*0201 
alleles. Variables were adjusted for potential confounders, includ-
ing age (in years), sex, nutritional status evaluated by the body mass 
index [BMI = weight/(height in meters)2], and baseline transami-
nase values. The patient’s sample size was determined from allele 
frequencies observed for healthy individuals with a genetic model 
analyzing the frequency for the disease gene with a RR value = 2 
(α = 0.05). The statistical power for variant alleles calculated for the 
sample size using healthy control population as a reference is 80% 
for unilateral association.1 A p value less than 0.05 was considered 
statistically significant.
1 Available from: http://www.allelefrequencies.net/. Consulted May 2016.
TaBle 2 | hla ii DQB1*0201 and DQA1*0102 analysis in patients with TB 
and with or without hepatotoxicity.
hla DQB1*0201 (presence) hla DQA1*0102 (presence)
Cases 30/55 (53.6%) 4/53 (7.5%)
Controls 25/55 (45.4%) 11/53 (20%)
p 0.38 0.12
OR, CI 95% 1.63, 0.62–4.52 0.36, 0.08–1.23
OR, odds ratio; CI, confidence interval.
Cases: patients with ATDH.
Controls: patients with no evidence of ATDH.
TaBle 1 | Baseline characteristics of cases and controls.
cases controls p
Age (years) 41 (15.8) 36.3 (15.5) <0.001
BMI (kg/m2) 23.5 (3.1) 22.8 (3.4) 0.12
Serum ALT (IU/L) 22 (7.7) 20.1 (9) 0.38
Serum AST (IU/L) 21.6 (5.8) 21 (6.6) 0.38
Variables are expressed as mean and SD (in parentheses). BMI, body mass index; ALT, 
alanine-transaminase; AST, aspartate transaminase; Normal intervals of serum ALT: 
4–40 IU/L; AST: 4–40 IU/L. IU, International units.
Cases: patients with ATDH.
Controls: patients with no evidence of ATDH.
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ethical issues
This investigation followed the tenets of the Helsinki declaration. 
It was approved by the Ethical Committee of Galicia (CEIC). 
Written informed consent was obtained from all participants. All 
participants were adults aged more than 18 years.
resUlTs
We included 110 TB patients, 55 with ATDH, and 55 controls 
with no evidence of this complication. The baseline characteristics 
are showed in Table 1. Hepatotoxicity was mild in 34% [median 
peak (IQR) of ALT, AST, GGT, and BIL of 154 IU/L (133–181), 
94  IU/L (72–117), 14  IU/L (30–59), and 0.4 mg/dL (0.3–0.65), 
respectively], moderate in 42.6% [median peak (IQR) of ALT, 
AST, GGT and BIL of 260 IU/L (220–337), 130 IU/L (108–198), 
87 IU/L (46–120), and 0.45 mg/dL (0.3–0.53), respectively] and 
severe in 23% [median peak (IQR) of ALT, AST, GGT, and BIL of 
953.5 IU/L (699–1126), 647 IU/L (239–826), 73 IU/L (61.2–139), 
and 0.45 mg/dL (0.3–1.01), respectively]. The median length of 
time from the beginning of treatment until the development of 
hepatotoxicity was 45 days (IQR, 22–69 days).
hla analysis
HLA DQA*0102 analysis was completed in 53 ATDH patients 
and in 53 controls. The frequency of the presence of HLA 
DQA*0102 was 7.5% in ATDH patients and 20% in non-ATDH 
patients with no significant differences between cases and 
controls (OR: 0.36 95% CI 0.08–1.23, p = 0.12) (Table 2). The 
analysis of the presence of HLA DQB1*0201 allele, completed in 
110 patients, did not show differences between both groups of 
ATDH cases and non-ATDH controls [53.6 vs. 45.4%, respec-
tively, OR: 1.63 95% CI (0.62–4.52) p = 0.38] (Table 2). When 
we performed the analysis by hepatotoxicity degree, we did 
not show differences in HLA DQA*0102 and HLA DQB1*0201 
presence in the different subgroups (mild, moderate, and 
severe hepatotoxicity). After multivariate logistic regression 
analysis including in the model, other potential risk factors 
of hepatotoxicity as advancing age, BMI, and pre-treatment 
transaminase values alterations in HLA class II DQB1*0201 
and DQA1*0102 alleles were not found significantly associated 
with the risk of development ATDH.
DiscUssiOn
This study performed in Caucasian origin TB patients showed 
no significant association between HLA DQA1*0102 absence and 
the risk of hepatotoxicity when the first-line standard therapy is 
used (INH, RIF, and PZA). However, there is a non-significant 
predominance of its absence in cases (92.5 vs. 80%). We also did 
not find an increased ATDH risk in HLA DQB1*0201 carriers. 
Most of the genetic risk in ATDH is focused in genes encoding 
drug-metabolizing enzymes that could explain interindividual 
variation in response and toxicity with ATD (6–11). However, 
other pathways of adverse drug reactions like hypersensitivity 
reactions should be deeply studied in ATDH. Different hypoth-
esis may explain immune-mediated reactions, and the major 
histocompatibility complex (MHC) class I or II molecules are 
always involved due to its crucial role in immune recognition 
(11). Interestingly, HLA variants have been linked to autoim-
mune hepatitis (7, 11, 12). Association of HLA variants has been 
described with different drugs as amoxicilin-clavulanate (16, 17), 
flucoxacilin (11), ximelagatran (11), lapatinib (18), lumiracoxib 
(19, 20), and neviparine (21). Sharma et  al. showed a fourfold 
increased risk of ATDH in patients without HLADQA1*0102 
haplotype suggesting to play a role in pathogenic development 
of ATDH (12).
Our investigation did not show association in an ethnically dif-
ferent group of TB patients, with a Caucasian origin from Spain. 
In a case-control study from China, exploring HLADQB1 alleles 
found that only DQB1*05/*05 positive genotype patients were 
in risk of ATDH after being adjusted by other protective drugs 
and weight. Sharma et al. also found, relevantly, the presence of 
HLADQB1*0201 in ATDH risk. In our study, these finding were 
not replicated too. An explanation could be the different ethnical 
origin of Sharma et  al. study population. Differences in HLA 
allele associations have been recently demonstrated between 
ethnical groups (7). There are few data to support an association 
between HLA alleles and ATDH risk; however, the results from 
the studies are heterogeneous probably due to small sample sizes 
and different ethnical origin (7).
Singer et al. have been described for the selective cyclooxy-
genase-2 inhibitor lumiracoxib an increased risk of liver disease 
secondary to lumiracoxib treatment linked to the presence of 
HLAQA1*0102 allele (OR = 5.0, 95% CI 3.6–7.0) (19). Probably, 
differences could be explained by the different hepatotoxic-
ity mechanism of non-steroidal drugs, and the interactions 
between several factors inherent to subjacent disease and the 
patients.
4Leiro-Fernández et al. HLA and Antituberculosis Drugs Hepatotoxicity Risk
Frontiers in Medicine | www.frontiersin.org August 2016 | Volume 3 | Article 34
One of the most important issues is to analyze the convenience 
of determining HLADQA1*0102 to predict possible hepatotoxic 
reaction to ATD that could lead to closer clinical and analytic 
monitoring of TB patients. However, after our results, we cannot 
make specific recommendations. The purpose of our study was not 
to analyze its relevance but rather a possible association between 
HLADQA1*0102 and the risk of ATDH in absence of other previ-
ously known ATDH risk factors. For that reason, the criteria of 
hepatotoxicity definition is low (three times de ULN AST/ALT) 
and not clinically relevant in most of the cases (1). Variations in 
the definitions of hepatotoxicity may have given rise to different 
results among studies. Another potential limitation of the study 
was that the sample size was small. It was due to the very strict 
inclusion criteria that exclude TB patients with any previously 
known ATDH risk factor. We are aware that the failure to find dif-
ferences in could be due to small sample so that the null hypothesis 
could be rejected when the alternative hypothesis is true (type II 
error). The analysis should, therefore, be replicated in a larger study 
with effective sample size, i.e., containing proband number that 
achieves adequate statistical power. Finally, we must consider the 
possibility of frequent bias of genetic case control. This was a nested 
case-control study design. However, it utilizes the exposure and 
the confounder data originally collected prior to the onset of the 
disease, thus reducing potential recall bias and temporal ambiguity 
(minor concerns in genetic case-control studies). Furthermore, 
nested studies include cases and controls drawn from the same 
cohort, thus decreasing the likelihood of selection bias.
cOnclUsiOn
We can conclude that even the absence of HLADQA1*0102 
could  be a risk factor associated with ATDH risk, we cannot 
demonstrate this association in a cohort of TB patients from 
Caucasian origin Spanish. We also could not demonstrate an 
association between HLADQB1*0201 and ATDH. More genetics 
investigations should be performed in conjunction with the rest 
of the genetic and clinical ATDH risk factors to determine its 
routine practical application in TB patients subsidiaries of treat-
ment with first-line ATD.
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